

EAACI Digital Congress 2020

- Final Programme -



[EAACI.org](https://eaaci.org)

[#eaaci2020](https://twitter.com/eaaci2020)



Bridging innovations into allergy and asthma prevention

Welcome to EAACI Digital Congress 2020!

Under the timely motto “Bridging innovations into Allergy and Asthma Prevention”, we are offering you the opportunity to explore our rich scientific programme in a truly innovative way. What better way to be updated on the conceptual and technological advances in our field, than by taking part in a brand-new technological approach to our EAACI Annual Congress?

During the Congress you will be able to:

- Tune in and watch a variety of virtual sessions in your own time and without missing out;
- Discuss important topics and ask your questions via an interactive Q&A;
- Consult our vast number of abstracts, posters and webcast symposia with novel research any time during the congress period;

In order to match this digital format, we have split our Scientific Programme in 3 parts:

Live Scientific Programme

A selection of the most exceptional sessions, to be delivered to you from June 6 to 8. You will find the details of this programme from pages 23 to 36.

Industry Programme

All the valuable content brought to you by our sponsors and exhibitors.

Recorded Scientific Programme

All the content originally included in the Scientific Programme prepared for the EAACI Congress 2020 in London:

- Symposia (SYM)
- Interactive Symposia (ISYM) and Workshops (IWS)
- Hot Topics (HT)
- Year in Review (YIR)
- Interactive Postgraduate Courses (IPGC)
- Pro & Cons (P&C)
- Ethics Sessions (ES)
- Sister Society Symposia (SSS)
- Late-Breaking Oral Abstract Sessions (LB OAS)
- Late-Breaking Poster Discussion Sessions (LB PDS)
- Late-Breaking Thematic Poster Sessions (LB TPS)
- Oral Abstract Sessions (OAS)
- Poster Discussion Sessions (PDS)
- Thematic Poster Sessions (TPS)

A selection of the content will be available for 6 months after the Congress.

Content

Welcome messages.....	4	Programme at a Glance - June 6.....	23
EAACI Committees.....	6	Programme at a Glance - June 7.....	28
General information.....	8	Programme at a Glance - June 8.....	33
EAACI future events.....	10	Speaker index.....	38
Ceremonies.....	15	National Society Village.....	40
Fellowship Winners.....	15	Sponsorship and Exhibition.....	42
EAACI Fellows 2020.....	16	Company Sponsored Symposia.....	46
EAACI Awards 2020.....	17	Exhibitor & Sponsor List.....	54
EAACI Activity Challenge.....	20	Exhibitor & Sponsor Editorials.....	56
Description of Session Types.....	21		

Addresses

EAACI Headquarters
Hagenholzstrasse 111
3rd Floor
8050 Zurich
Switzerland
Tel: +41 44 205 55 33
info@eaaci.org
www.eaaci.org

EAACI Digital Congress 2020 Online Platform
<https://virtual.eaaci.org/>

EAACI Technical Support
support@eaaci.org

General Enquiries
congress@eaaci.org

Congress Registration
registration@eaaci.org

Welcome messages

Bridging innovations into allergy and asthma prevention

It is my great pleasure to invite you to the first ever digital EAACI Annual Congress 2020, which will be held from 6 to 8 June.

In the next few years, medical innovations will fundamentally revolutionize the healthcare system, with the goal of improving peoples' quality of life. This year's Congress motto suggests that we will not only present state-of-the-art knowledge in allergy and clinical immunology but will go beyond this, bridging it with the most contemporary, inspiring and creative processes and ideas diffused and adapted to the needs of our patients.

Modern times also foster the revival of the old definition of innovation as a synonym for rebellion or revolt. Change is not only about embracing new ideas but also about leaving outdated ones behind, and what better opportunity to do so than taking part in this completely new format of Annual Congress?

Do not miss the chance to take part in the modern allergology paradigm shift driven by new discoveries: endotype and theratype approaches that change not only the taxonomy but the way we perceive and manage the allergic disease. The interactive sessions and discussions designed to match the expectations of all participants will provide a platform to stimulate the creativity of thousands of delegates, and the high-throughput screening of viable solutions using the innovative digital format.

Join us at the EAACI Congress 2020!

Marek Jutel
EAACI President 2019-2021



See you all online for the EAACI Digital Annual Congress!

On behalf of the Local Organising Committee, it is with great pleasure to invite you to the EAACI Annual Congress 2020, which this year will take part digitally from 6- 8 June.

Our world is everchanging, and with the advent of new technologies in medicine: omics, big data, mHealth and the development of artificial intelligence among others, this congress will provide a unique opportunity to foster and discuss these avenues in our field. The future includes tackling allergic diseases and asthma at their root, and these discoveries will be powerful tools to work towards prevention in our field.

You will be able to explore the same quantity and quality of scientific content that you would have experienced during our traditional Congress in London - while staying safe at home and benefiting financially.

Besides full access to the Digital Congress content, including Keynote symposia, state-of-the-art symposia, industry symposia, oral and poster presentations – you will also benefit from access to these resources for 6 months after the event.

We look forward to welcoming you to this new format of EAACI Congress where we will push boundaries with forward thinking and novel approaches to preventing allergy and asthma worldwide.

Mohamed Shamji
EAACI Digital Congress 2020 Chair



BECOME AN EAACI MEMBER

Over 12,000 professionals are already members of the largest medical association in Europe in the field of Allergy and Clinical Immunology.

Benefits applied to all categories

- ✓ Free subscription to online Allergy and PAI journals
- ✓ Possibility to join Task Forces
- ✓ Full voting rights & eligibility for election
- ✓ 50% Discount EAACI Knowledge Exam

Full Membership

150€*

- ✓ EAACI Annual Congress Up to 25% discount
- ✓ EAACI Focused Meetings 25% discount
- ✓ EAACI Schools & Master Classes Up to 40% discount
- ✓ Subscription to printed journals (upon request)

** For members from countries with a GNP of less than USD 10,000: Full Membership is 75€ and EAACI Allied Health Interest Group Membership is 40€.*

Junior Membership (under 36 years old)

Free

- ✓ EAACI Annual Congress Up to 55% discount
- ✓ EAACI Focused Meetings Up to 70% discount
- ✓ EAACI Schools & Master Classes Up to 50% discount
- ✓ Eligibility for EAACI fellowships & Scholarships
- ✓ Eligibility for EAACI events travel grants
- ✓ Printed subscriptions for Allergy & PAI is an additional 60€ per year

EAACI / NAS Dual Membership

30€

- ✓ EAACI Focused Meetings 25% discount
- ✓ EAACI Schools & Master Classes Up to 40% discount
- ✓ Printed subscriptions for Allergy & PAI is an additional 60€ per year

This membership only applies to members of National Societies who have signed the EAACI NAS Dual Membership Agreement. Check our National Societies Agreements list at www.eaaci.org/membership



EAACI Committees



EAACI Executive Committee

EAACI Board of Officers

Marek Jutel, President
 Jürgen Schwarze, Secretary General
 Liam O'Mahony, Treasurer
 Edward Knol, Vice-President Congresses
 Stefano del Giacco, Vice-President Education & Specialty
 Karin Hoffmann-Sommergruber, Vice-President Communications & Membership
 Tomás Chivato, Vice-President Science
 Ioana Agache, Past President

EAACI Section Chairpersons

Matteo Bonini, Asthma Section
 Charlotte Mortz, Dermatology Section
 Ludger Klimek, ENT Section
 Eva Untersmayr-Elsenhuber, Basic & Clinical Immunology Section
 Helen Brough, Pediatrics Section
 Carmen Riggioni, Junior Members Section
 Radoslaw Gawlik, Allied Health and Primary Care Section

EAACI Interest and Working Group Representatives

Jolanta Walusiak-Skorupa
 Oscar Palomares

Members at Large

Oliver Pfaar
 Maria Torres
 Isabel Skypala
 Antti Lauerma
 Markus Ollert
 Asli Gelincik

Local Organising Committee (LOC)

Mohamed Shamji, EAACI Digital Congress 2020 Chair
 Helen Brough, EAACI Digital Congress 2020 Co-Chair
 Liam O'Mahony, EAACI Digital Congress 2020 Co-Chair
 Shuaib Nasser, EAACI Digital Congress 2020 Co-Chair

Stephen Durham
 Adam Fox
 Clive Grattan
 Isabel Skypala
 Adnan Custovic
 Fan Chung
 Rebecca Knibb

Jonathan Hourihane
 Shelley Dua
 Hassan Arshad
 Ian Adcock
 George du Toit
 Nicola Brathwaite
 Glenis Scadding
 Madison Lenormand
 Roisin Fitzsimons
 Paul Turner
 Tabi Leslie
 Sebastian Johnston

EAACI Committees



Scientific Programme Committee (SPC)

Scientific Programme Committee 2020

Mohamed Shamji, Scientific Programme Committee Chair 2018-2020
 Mohamed Shamji, EAACI Congress 2020 Chair
 Marek Jutel, EAACI President 2019-2021
 Ioana Agache, EAACI Past President 2017-2019
 Jürgen Schwarze, EAACI Secretary General 2019-2021
 Edward Knol, EAACI VP Congresses 2019-2021
 Carsten Schmidt-Weber, EAACI VP Congresses 2017-2019
 Tomas Chivato, EAACI VP Science 2019-2021
 Helen Brough, EAACI Congress 2020 Co-Chair
 Nasser Shuaib, EAACI Congress 2020 Co-Chair
 Liam O'Mahony, EAACI Congress 2020 Co-Chair
 Luis Delgado, EAACI Congress 2019 Chair

Section Secretaries 2019 – 2021

Milena Sokolowska, Basic & Clinical Immunology
 Ibon Equiluz-Gracia, Asthma
 Stefania Arasi, Pediatrics
 Barbara Ballmer-Weber, Dermatology
 Sanna Toppila-Salmi, ENT
 Pasquale Combierati, JM Assembly
 Rosan Meyer, Allied Health & Primary Care

Section Secretaries 2017 – 2019

Eva Untersmayr-Elsenhuber, Basic & Clinical Immunology
 Matteo Bonini, Asthma
 Lauri-Ann Van der Poel, Pediatrics
 Charlotte Mortz, Dermatology
 Ludger Klimek, ENT
 Alberto Alvarez-Perea, JM Assembly

Interest Group Chairs 2019 – 2021

Alexandra Santos, Food Allergy
 Marina Atanaskovic-Markovic, Drug Allergy
 Montserrat Alvaro Lozano, Allergen Immunotherapy
 Mohamed Jeebhay, Environmental and Occupational Allergy
 Bernadette Eberlein, Allergy Diagnosis & Systems Medicine

Interest Group Chairs 2017 – 2019

Margitta Worm, Food Allergy
 Marina Atanaskovic-Markovic, Drug Allergy
 Lars, Jacobsen, Allergen Immunotherapy
 Monika Raulf, Environmental and Occupational Allergy
 Paolo Matricardi, Allergy Diagnosis & Systems Medicine
 Elizabeth Angier, Allied Health & Primary Care

Working Group Chairs 2019 – 2021

Anna Sediva, Immunodeficiencies
 Wojciech Feleszko, Infections
 Thomas Eiwegger, Biologicals
 Maia Rukhadze, Allergy, Asthma & Sport
 Banu Bozkurt, Ocular Allergy
 Antonella Cianferoni, Eosinophilic Eosinophagitis
 Gunter Sturm, Insect Venom Hypersensitivity
 Grzegorz Brozek, Epidemiology
 Carmen Galan, Aerobiology & Air Pollution
 Maria Escribese, Genomics & Proteomics
 Isabella Pali-Schöhl, Comparative Veterinary Allergology
 Audrey Dunn Galvin, Allied Health
 Elizabeth Angier, Primary Care

Working Group Chairs 2017 - 2019

Isabella Quinti, Immunodeficiencies
 Hermelijn Smits, Infections
 Oscar Palomares Gracia, Biological
 Mariana Couto, Allergy, Asthma & Sport
 Jean-Luc Fauquert, Ocular Allergy
 Ingrid Terreehorst, Eosinophilic Eosinophagitis
 Hanneke Oude Elberink, Insect Venom Hypersensitivity
 Jon Genuneit, Epidemiology
 Michel Thibaudon, Aerobiology & Air Pollution
 Cornelis M. Van Drunen, Genomics & Proteomics
 Jozef Janda, Comparative Veterinary Allergology
 James Gardner, Allied Health
 Radoslaw Gawlik, Primary Care



General information

About EAACI

The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organisation active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis. EAACI was founded in 1956 in Florence and has become the largest medical association in Europe in the field of allergy and clinical immunology. It includes over 12'000 members from 120 countries, as well as over 75 National Allergy Societies.

Visit www.eaaci.org for more information.

Abstracts

All abstracts will be listed on the EAACI website as of Saturday, 6 June 2020. Presented abstract (except DCPD) texts will be published on the [EAACI Media Library](#) and in the official [EAACI Journal Allergy](#) after the congress.

Certificate of Attendance

The Certificate of Attendance can be downloaded after completing the delegates survey, which will be sent via email approximately two weeks after the digital congress.

CME Credits

The EAACI Digital Congress 2020, 06-08/2020 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 22 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Click [here](#) for more information.

Congress Scholarship

Due to the change of format, we regret to inform you that there will be

no Scholarships for the EAACI Digital Congress 2020. Nevertheless, we are pleased to make the Digital Congress registration free of charge for Junior Members.

Disclaimer

Participants are encouraged to purchase an insurance to cover loss incurred in the event of cancellation. EAACI cannot be held liable for any hindrance or disruption of the EAACI Digital Congress 2020 proceedings arising from natural, political, social or economic events or other unforeseen incidents beyond its control (force majeure). Registration of a participant implies acceptance of this condition. The materials presented at this continuing medical education activity are made available for educational purposes only.

EAACI Campus

Visit the EAACI Campus virtual booth to learn more about EAACI's activities such as membership, publications, EAACI Media Library and future events is available under one roof. The booth will be open throughout the entire congress, and an online team will be available for questions through the live chat during the following opening hours:

Saturday, 6 June, 09:00 – 17:30 CET
Sunday, 7 June, 09:00 – 17:30 CET
Monday, 8 June, 09:00 – 17:30 CET

Language

The official language of EAACI Digital Congress 2020 is English.

Virtual Exhibition

Join us in meeting with key industry experts, exchange knowledge on critical areas of development and research in allergy and immunology. The digital

exhibition will be open according to the main scientific programme timetable, subject to final adjustments.

Start of Virtual Exhibition:

6 June 2020 – 9:00 (CET)

End of Virtual Exhibition:

6 December 2020 – 17:30 (CET)

General Assembly

EAACI's General Assembly will take place remotely during the EAACI Digital Congress 2020 on **Monday 08 June, 08:00-09:00 CET**. The General Assembly is an opportunity to be informed about current activities and future plans, and to actively participate in the life of the Academy.

You will be able to access the General Assembly on Monday 08 June 2020 at 08:00 CET by logging in with your EAACI member number and password. Please note that only members with voting rights (in good standing) will be able to vote. [Please click here](#) to log into your membership profile and settle any outstanding fees for your 2020 membership. Payment must be done by Friday 05 June 2020 at 19:00 CET in order to gain access to the voting platform on Monday 08 June 2020.

National Society Village

The National Society Village is open throughout the entire Digital Congress and features the virtual booths of our NAS from all over Europe. At each booth you will be able to visualise brochures, watch videos, consult important national resources and much more. You will also have the chance to interact with respective members of the NAS through an e-mail form. We encourage you to visit this area to learn more about your country's very own society dedicated to allergy, asthma and immunology, or explore developments in the field from other countries!

General information

Poster Exhibition Information

• **Thematic Poster Sessions (TPS):** TPS can be found in the e-poster section of the Digital Congress, together with a voice-over, and will be available in the EAACI Media Library.

• **Poster Discussion Sessions (PDS):** PDS can be found in the e-poster section of the Digital Congress, together with a voice-over, and will be available in the EAACI Media Library.

• **Digital Congress Poster Display (DCPD):** DCPD can be found in the e-poster section during the Digital Congress.

Photography, film and audio for event documentation and public reporting

By participating in the EAACI Digital Congress 2020 the delegate understands that recordings of the digital content and the capture of images and

videos to be publicly shared are prohibited.

Press contact details

EAACI Public Affairs Specialist:
Chiara Hartmann.

Office number: +41 44 205 55 34

Email: chiara.hartmann@eaaci.org

Registration

Registration fee for delegates includes full access to the EAACI Digital Congress 2020 content including plenary talks, symposia, workshops, industry symposia, oral and poster presentations during the Congress and for 6 months after the event.

Technical Information

The EAACI Digital Congress 2020 interface will be user-friendly and fully responsive, allowing delegates to watch all sessions from their laptops/

desktops, iPad/tablets, and mobile phones. However it is recommend to use computers, to get the best experience including live chat during sessions within the Live Scientific Programme, an important feature that boosts interaction between you, faculty and your peers. In regards to a preferable web browser, we suggest Google Chrome as the most compatible one. In order to provide a well streamlined support, we kindly ask you to send any technical queries directly to following email address: support@eaaci.org.

EAACI Newsletter

Eager to get the latest news on our activities, events, and perspectives from the EAACI Family?

Read our latest issue of the EAACI Newsletter which features a glimpse into the exciting programme of the Digital Congress, COVID-19 viewpoints from our doctors and researchers on the frontline, and much more!





Focused Meetings



FAAM 2020 - Food Allergy and Anaphylaxis Meeting

15-17 October 2020 / Manchester, United Kingdom

For the sixth consecutive time FAAM 2020 will be the leading event in the area of food allergy and anaphylaxis where internationally acclaimed speakers will share their knowledge. The meeting's programme will bring you the most recent research, opinion and best practice in the field of food allergy and anaphylaxis in children and adults, delving into the molecular and cellular mechanisms of food allergy and anaphylaxis, practicalities of diagnosis and patient management and exciting new developments for prevention and treatment.



EUROBAT 2020 - European Consortium on Application of Flow Cytometry in Allergy

15 October 2020 / Manchester, United Kingdom

The sessions of EUROBAT will cover the current applications of BAT in food allergy, insect allergy, drug hypersensitivity, urticaria as well as future and new developments. Each session will have invited speakers and open presentations based on abstract submissions. The event will also involve an interactive roundtable discussion on the topic "Globalized exchange of experiences for BAT quality assurance" with all attendees and invited guests.



ISAF 2020 - International Severe Asthma Forum

22-24 October 2020 / Rome, Italy

ISAF is a cutting edge and evidence-based EAACI Focused Meeting with a scientific programme including a broad range of session formats and designed to facilitate interactive and stimulating discussions. Among key topics of the 2020 edition there will be precision medicine, electronic-health, big data, microbiome, pharmacogenomics, medical devices, breathomics and regulatory aspects. Special relevance will be also given to severe asthma in children and during pregnancy.



DHM 2021 - Drug Hypersensitivity Meeting

Spring 2021 / Verona, Italy

The EAACI Drug Hypersensitivity Meeting (DHM 2021) taking place in Spring 2021, in Verona, Italy, is an interdisciplinary meeting, bringing together researchers and physicians from different disciplines. It is the leading event of its kind, attracting up to 600 physicians and researchers from all over the world.



SAM 2021 - Skin Allergy Meeting

11 - 13 March 2021 / Copenhagen, Denmark

Held in collaboration with the European Society for Contact Dermatitis (ESCD), SAM 2021 will give up to date information for clinicians and cover basic, translational and clinical aspects on diseases such as atopic dermatitis, contact dermatitis, occupational eczema and more. To increase the learning experience, practical courses, interactive workshops and case reports with an important "teaching point" will be implemented in addition to keynote lectures given by experts from top-level international institutions.

Allergy Schools & Master Classes



Allergy School on Anaphylaxis: Etiology Prevention and Management

Autumn 2020 / Izmir, Turkey

Anaphylaxis with its life-threatening potential has always been one of the most important emergencies for all clinicians. Therefore, it is essential to review the information we have in order to keep up with the recent advances. In lectures and interactive workshops, the Allergy School will host discussions regarding the causes, initiators and co-factors of anaphylaxis, possible preventive measures and management of anaphylaxis.



Master Class on Perioperative Hypersensitivity

Spring 2021 / Verona, Italy

The Master Class on Perioperative Hypersensitivity will provide a contemporary understanding of the clinical presentation, common causes and diagnostic work-up of patients referred for the investigation of perioperative hypersensitivity. The event's faculty will focus on the importance of collaboration between allergists/immunologists and anaesthesiologists and will include absolute experts in the field presenting the latest evidence and their own practical experiences.

Due to COVID-19, some of our event dates and formats might be subject to change. More 2021 events will be announced shortly.

Thousands of resources now available on EAACI Media Library


Guidelines
Abstracts
Books
Posters
Papers

Newsletters

Webcasts



All EAACI Resources are only **1 click away**





EAACI Digital Congress

6-8 June 2020

Bridging Innovations into
Allergy and Asthma Prevention

#EAACI2020

Ceremonies

Welcome Ceremony

At the kick-off our EAACI 2020 Digital Congress tune in to three top-level Opening Keynote lectures under the theme of "Solutions and Challenges in Modern Medicine". Explore present-day findings in relation to the COVID-19 pandemic and our field, and listen to Sir Gregory Winter, Nobel Prize Winner for Biochemistry address the way forward for biologicals in modern medicine. In addition to these stimulating sessions, get the virtual feel of an exciting congress to come through welcome talks by our EAACI President and EAACI Congress Chair, and find out who these year's recipients of our prestigious EAACI Awards are.

Closing Ceremony

At the close of our first digital Congress, we already look forward to the next opportunity for our community to meet in Madrid for the EAACI Congress 2021. The closing ceremony will give you a glimpse into its preparations, theme and programme through addresses from our 2021 Local Organising Committee. In addition, our EAACI President and Congress Chair 2020 take this opportunity to thank all participants and look back to this Congress' successes and highlights.

Fellowship Winners

Name	Country	Name	Country
Clinical Fellowships (3 months duration)		Research Fellowships Short-term Research Fellowships (3 months duration)	
Mattia Giovannini	United Kingdom	Gustavo Jorge Molina	Belgium
Christos Fokoloros	Germany	Kristin Boykova Boteva	Germany
Huyen Thanh Thuc	France	Mario Lovric	Denmark
Carina Petricau	United Kingdom	Sandip D Kamath	Austria
Johnson Nameirakpam	Italy		
Deniz Eyice Karabacak	Austria		
Fatma Esra Gunaydin	United Kingdom		
		Medium-term Research Fellowships (6 months duration)	
		Jialing Jiang	United Kingdom
		Angelika Tscheppe	Belgium
		Amri Manel	Denmark
		Long-term Research Fellowships (12 months duration)	
		Ruben Fernandez Santamaria	Switzerland
		Didem Sanver Akbas	United Kingdom
		Carole Florence Guillet	United Kingdom
		Karolina Dumycz	Germany



EAACI Fellows



EAACI recognizes excellence in basic and clinical research in the field of allergy and clinical immunology and awards the title of EAACI Fellow to EAACI members who have excelled in their field. EAACI fellows will form an elite advisory board that will be called upon by the Academy on various matters in future years.



Claudia Traidl – Hoffmann
EAACI Fellow for Clinical Research

Dr. Traidl-Hoffmann has been awarded the FEAACI in 2020 for her continuous excellence on environment-human and environment-environment interaction with a focus on the barrier function of border surfaces, and the effects of climate change on environment and health.



Giorgio Walter Canonica
EAACI Fellow for Clinical Research

Dr. Canonica has been awarded the FEAACI in 2020 for his continuous excellence in investigating the different T lymphocytes subsets and their functional role in basic and clinical research (Allergy, Organ specific autoimmunity, CNS degenerative diseases and cancer), and the molecular events and interactions between immunocompetent cells.



Nikolaos Papadopoulos
EAACI Fellow for Research

Dr. Papadopoulos has been awarded the FEAACI in 2020 for his continuous excellence in understanding of the role on infections in asthma, and basic, translational and clinical aspects of allergy, from molecule characterisation to clinical trials.



Sebastian Johnston
EAACI Fellow for Research

Dr. Johnston has been awarded the FEAACI in 2020 for his continuous excellence in addressing the mechanisms of acute exacerbations of asthma and interactions between respiratory infections and allergic disease, and development of human and mouse in vivo models of rhinovirus.

EAACI Awards 2020



Each year, EAACI honours European researchers and clinicians who have contributed significantly to the development of innovative diagnostic and therapeutic strategies for control and prevention of allergic diseases, to the understanding of their pathophysiology and to the strengthening of allergology as a specialty in Europe. The EAACI Awards 2020 will be presented during the Opening Ceremony - Saturday, 6 June 2020 at 19:45 CET.

Paul Ehrlich Award for Experimental Research 2020 - Mübeccel Akdis



Dr Akdis graduated from the Medical faculty of Uludag University, Bursa-Turkey in 1985. She is working at the Swiss Institute of Allergy and Asthma Research (SIAF) since 1995 and received her PhD in Immunology. Dr Akdis worked as a postdoctoral scientist and became a group leader at SIAF, where she has established her own research group in 2003. Dr Akdis made her habilitation (Venia Legendi) at the Zurich University Medical Faculty on Experimental Immunology in 2005 and became a professor in 2015. She has published more than 231 Peer-reviewed articles, Sum of times cited: 18'580 and her h-index: 74 (90-Google scholar). Her major research contributions are on mechanisms of allergen tolerance, high dose allergen exposure models in humans, mechanisms of allergen-specific immunotherapy, functions of T regulatory cells, NK regulatory cells and recently IL-10 producing human B regulatory cells. Demonstration of immunological effects of rhinoviruses on T and B cells and breaking of immune tolerance to allergens, Demonstration of an angiogenesis promoting novel B cell subset. She has received research grants and collaborative grants from the Swiss National Foundation, European Union and Sean Parker Seed Grant. She received numerous awards, including Ferdinand Wortman Prize, Professor Hans Storck Award, Sedat Simavi Medicine Award, International Distinguished Fellow Award of the American College of Allergy, Asthma & Immunology (ACAAI), 2018. She is a board member of the World Allergy Organization (WAO) and has taken active roles in the organization of several EAACI Davos, Immunology Winter Schools and all the World Immune Regulation Meetings (WIRM) since their initiation in 2007.

Charles Blackley Award for the Promotion of the Specialty 2020 - José María Olaguibel



Jose M^a. Olaguibel is active in clinical allergy practice, teaching (Clinical Assistant Professor of Medicine, Universidad de Navarra), and clinical research (Navarrabiomed.es), with a special interest in respiratory allergy, including lung function and airway inflammation, asthma diagnosis, and immunotherapy with allergens. He has produced more than 100 original articles published in international scientific journals (H index 28). He is a member of the American Academy of Asthma, Allergy and Clinical Immunology, the European Academy of Allergy and Clinical Immunology and the Spanish Society of Allergy and Clinical Immunology (Past President). By now, he is the Editor in Chief of the Journal of Investigational Allergology and Clinical Immunology (FI: 3,8), and has been recently involved in the development of the Spanish guidelines for asthma diagnosis and management (GEMA 5.0).



Each year, EAACI honours European researchers and clinicians who have contributed significantly to the development of innovative diagnostic and therapeutic strategies for control and prevention of allergic diseases, to the understanding of their pathophysiology and to the strengthening of allergology as a specialty in Europe. The EAACI Awards 2020 will be presented during the Opening Ceremony - Saturday, 6 June 2020 at 19:45 CET.



Daniel Bovet Award for Treatment and Prevention 2020 – George du Toit

George du Toit is Professor of Paediatric Allergy, Evelina London Children's Hospital, Guy's and St Thomas' NHS Trust and Kings College London. George is active in clinic research currently focusing on the LEAP-Trio and EAT-On food allergy prevention studies, the BAT II diagnostic study, and oral and epicutaneous peanut desensitisation trials. George is lead clinician for the Children's Drug Allergy service at Evelina London Children's Hospital and past Chairperson of the European Academy of Allergy and Clinical Immunology (EAACI) Paediatric Section.



Clemens von Pirquet Award for Clinical Research 2020 - Santiago Quirce

Santiago Quirce is Head of the Allergy Department at La Paz University Hospital, Professor of Respiratory Medicine at Universidad Autónoma of Madrid, and Director of the Research group on Allergic diseases at La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. He graduated in Medicine from the University of Santander and obtained his Ph.D. degree at the University of Cantabria, Spain, and received the Distinguished Alumni Award from this University in 2014. He did his post-graduate training as Research Fellow at Vancouver General Hospital, Respiratory Division, University of British Columbia, Canada. Dr. Quirce has edited and authored numerous publications, including 12 books and over 400 peer-reviewed papers. He has been a member of the Executive Committee of EAACI as representative of the Interest Groups, and Secretary of the Spanish Society of Allergy and Clinical Immunology.



Each year, EAACI honours European researchers and clinicians who have contributed significantly to the development of innovative diagnostic and therapeutic strategies for control and prevention of allergic diseases, to the understanding of their pathophysiology and to the strengthening of allergology as a specialty in Europe. The EAACI Awards 2020 will be presented during the Opening Ceremony - Saturday, 6 June 2020 at 19:45 CET.



PhARF Award 2020 – Paul Turner

Dr Paul Turner is a Clinician Scientist and Honorary Consultant in Paediatric Allergy & Immunology at Imperial College London, and Clinical Associate Professor at the University of Sydney, Australia. His research focusses on the pathophysiology of severe allergic reactions to food, and how this impacts upon allergen risk management and the use of precautionary allergen labelling. He leads the food allergy desensitisation programme at St Mary's Hospital, London; the team was awarded the Best UK Clinical Team by Allergy UK in 2018. Paul's research is funded by the Medical Research Council, FSA, European Commission, NIHR and EAT Foundation (USA). He is a visiting Honorary Consultant at a number Central London Hospitals, a paediatric consultant on allergy-related issues to Public Health England, and current Chair of the BSACI Paediatric Allergy Group and the WAO Anaphylaxis Committee. He is a member of the UK Food Standards Agency's Science Council.



Allergopharma Award – Rodrigo Jiménez Saiz

Rodrigo Jiménez-Saiz is a Junior Group Leader at the Dept. of Immunology and Oncology at the National Center for Biotechnology (CNB-CSIC, Madrid, Spain) and a part-time Assistant Professor at the Dept. of Pathology and Molecular Medicine (McMaster University, Hamilton, Canada). He is also a part-time Teaching Professor of Biomedicine at the Universidad Francisco de Vitoria (Madrid, Spain) and a Visiting Researcher at the Spanish National Center for Cardiovascular Research (CNIC, Madrid, Spain). The Jiménez-Saiz Lab aims to understand immunological principles of Th2 immunity in the context of allergic disease, particularly as it pertains to acute allergic reactions (anaphylaxis) and its modulation by the microbiota, the maintenance of IgE immunity (memory responses), and the impact of allergic disease in the development of other pathologies. Rodrigo Jiménez-Saiz is an elected member of the Immunology Section of EAACI, Chair of a EAACI Task Force on public outreach and member of the Scientific Committee of FAAM 2020. He serves on a number of Editorial Boards including Allergy, International Archives of Allergy and Immunology, and Frontiers in Allergy, and was recently nominated Top Peer Reviewer in Immunology by Publons.

EAACI Activity Challenge



Overview

The Digital congress delegates will be able to earn points at several check points and interactions along the way during the EAACI Digital Congress 2020 experience.

Available to all registered delegates during their visit to the virtual exhibition area when visiting, chatting, answering scientific questions, and providing valuable feedback to our industry partners.

Additionally, with the Leaderboard function, delegates will be able to see the live scores of the top 20 delegates.

EAACI would like to thank our Industry Sponsors for their support and dedication during these difficult times, this could not be done without the valuable contributions from them.

The digital information exchange at EAACI 2020 represents a new and exciting experience for us all. We encourage you to explore it all! Use your well-deserved breaks to network, inform and exchange.



Activity Challenge EAACI Digital Congress 2020

How does it work?

- Once you have logged on to the EAACI 2020 Platform, the Activity challenge will appear on the Home Page. Click on the Activity Challenge icon which will prompt a description of the activities.
- Goal is to generate as many points as possible from the group of activities listed.
- Each activity will have a maximum amount of points that can be achieved, which will be distributed based on how much the attendee has completed.
- As activities progresses, there are barriers that shows:
 - Activity completion status. Eg. You have completed 5/10 activities
 - Participants point total can be seen next to their profile.
- In the case of multiple participants in the EAACI Activity Challenge tied with the most points on the overall points table, the winner will be automatically be identified based on the submission time of first completing the full Activity Challenge.

Description of Session Types



Company Sponsored Symposia

Industry Symposia will run in parallel with the main scientific programme on the digital programme. These symposia are organised independently by the sponsoring companies who also select the topics and speakers which are approved by the Scientific Programme Committee.

Digital Congress Poster Display (DCPD)

Digital Congress Poster Display (former On-Site Poster Display) can be found in the e-poster section of the Digital Congress. DCPD will not be published in the EAACI Media Library and the official journal of EAACI after the Congress.

Ethics Session (ES)

Ethics Session is a state of the art symposium in which the speakers critically review ethical aspects of topics related to Allergy and Clinical Immunology. The target audience consists of delegates who are primarily interested in the subject or wish to update their knowledge in the area. The Ethics Session will be available in the Recorded Scientific Programme only.

Hot Topics (HT)

Hot Topic Sessions consist of presentations. Topics are selected close to the time of the congress, with the goal of presenting new and exciting data in a more informal format than a typical session. Hot Topic Sessions allow members to gain insight into the latest news and findings in allergy and clinical immunology.

Interactive Symposia (ISYM) and Workshops (IWS)

Interactive Workshops are sessions in which speakers share and discuss evidence and experience gathered - clinical and/or basic - in a certain field. These sessions are interactive, and the speaker addresses some frequently asked questions with regards to the topic.

Interactive Postgraduate Courses (IPGC)

Interactive Postgraduate Courses are educational sessions where the speaker addresses some frequently asked questions with regards to the topic.

Keynote Symposia (KL)

Keynote Symposia are the core of the congress activities. These are exhaustive reviews of a major subject of the specialty, addressed to all congress participants. Plenary Symposia are scheduled at "prime times" in the programme, with no crossover with other activities to enable maximum attendance.

Late-Breaking Oral Abstract Sessions (LB OAS)

The most exciting work from late-breaking abstracts submitted to the congress will be honoured with a place in these sessions. Each presenter highlights their work.

Late-Breaking Poster Discussion Sessions (LB PDS)

LB PDS can be found in the e-poster section of the Digital Congress, together with a voice-over, and available in the EAACI Media Library.

Late-Breaking Thematic Poster Sessions (LB TPS)

LB TPS can be found in the e-poster section of the Digital Congress, together with a voice-over, and available in the EAACI Media Library.

Oral Abstract Sessions (OAS)

The most exciting work from abstracts submitted to the congress will be honoured with a place in these sessions. Each presenter highlights her/his work.

Poster Discussion Sessions (PDS)

PDS can be found in the e-poster section of the Digital Congress, together with a voice-over, and available in the EAACI Media Library.

Pro & Cons (P&C)

The Pro & Con Sessions allow speakers to debate controversial topics in an attractive format which provides "food for thought". The Pro & Con Sessions will be available in the Recorded Scientific Programme only.

Sister Society Symposia (SSS)

EAACI has collaborated with a number of sister societies to develop symposia that represent regional or scientific areas common to EAACI and the sister society. This is a chance to expand your knowledge beyond the traditional boundaries. There will be 6 live SSS and the remaining ones will be available in the Recorded Scientific Programme only.

Description of Session Types



Symposia (SYM)

Symposia are state-of-the-art educational sessions in which the speakers critically review diverse aspects of a specific topic. The target audience consists of delegates who are primarily interested in the subject or wish to update their knowledge in the area. There will be 9 live SYM and the remaining ones will be available in the Recorded Scientific Programme only.

Thematic Poster Sessions (TPS)

TPS can be found in the e-poster section of the Digital Congress, together with a voice over, and available in the EAACI Media Library.

Year in Review (YIR)

The Year in Review Sessions are complete and authoritative, focused on the highlights published during the previous year on a specific topic.

Important Notice

Due to the change of format, we regret to inform you that the following sessions will not be part of the EAACI 2020 Digital Congress:

- Allied Health Day
- Business Meetings (BM)
- Company Sponsored Mini Symposia (CSMS)
- Clinical Village
- EAACI Immunology Course
- Learning Lounges (LL)
- Satellite Symposia (SAT)

Programme at a Glance



Saturday, 6 June 2020

This page gives an overview of the digital sessions organised on June 6, 2020. The original scientific programme created for the EAACI Congress 2020 in London includes much more content. It is possible to access this “Recorded Scientific Programme” by clicking on the link button on the right.

[Recorded Scientific Programme](#)

CET Time	Track 1 Live Scientific Programme	Track 2 Industry Programme
09:00	09:00 - 10:25 CET KS 1 - Keynote Symposia The challenges of severe Asthma	
09:15		
09:30		
09:45		
10:00		
10:15		
10:30	Digital break	
10:45	10:45 - 12:15 CET SYM 1 - Symposia Novel insights into the development of allergic disease	10:30 - 11:45 CET CSS 1 - Company Sponsored Symposia
11:00		
11:15		
11:30		
11:45		
12:00		
12:15	Digital break	12:00 - 13:15 CET CSS 2 - Company Sponsored Symposia
12:30	12:45 - 14:15 CET SYM 2 - Symposia Food Allergy: prevention is better than cure	
12:45		
13:00		
13:15		
13:30		
13:45		13:30 - 14:45 CET CSS 3 - Company Sponsored Symposia
14:00	14:45 - 16:15 CET SYM 3 - Symposia Biologicals and other therapies in allergy: from clinical trials to clinical practice	
14:15		
14:30		
14:45		
15:00		
15:15		
15:30	16:45 - 17:45 CET SSS 1 - Sister Society Symposium EAACI - NIAID/NIH Joint Symposium: from bed to bench side	16:30 - 17:45 CET CSS 5 - Company Sponsored Symposia
15:45		
16:00		
16:15		
16:30		
16:45		
17:00	Digital break	
17:15	18:15 - 19:15 CET SSS 2 - Sister Society Symposium EAACI - ACAAI joint symposium: atopic dermatitis: what's new?	
17:30		
17:45		
18:00		
18:15		
18:30		
18:45	19:50 - 20:00 CET Welcome Ceremony 20:00 - 20:50 CET Opening Keynote Lectures 20:50 - 21:05 CET EAACI Awards	
19:00		
19:15		
19:30		
19:45		
20:00		
20:15		
20:30		
20:45		
21:00		
21:15		



Programme description

Saturday, 6 June 2020

KS 1 The challenges of severe asthma

Saturday, 6 June 2020 - 09:00-10:25 CET

Learning objectives:

- To discuss the role of microbiome in allergy and asthma.
- To discuss the role of exposome and asthma.
- To discuss the utility of machine learning and algorithms in asthma management.
- To discuss factors that influence asthma development from childhood to adulthood.

Chairs

Matteo Bonini (Italy), Liam O'Mahony (Ireland)

The airway microbiome in asthma development - Q&A

Benjamin Marsland (Australia)

Exposomes and gene interaction in asthma - Q&A

Kian Fan Chung (United Kingdom)

Trajectory of lung disease from childhood to adulthood - Q&A

Patrick Holt (Australia)

Big data and cluster analysis: a real life perspective - Q&A

Ioana Octavia Agache (Romania)

Launch of the Biological guidelines - Q&A

Ioana Octavia Agache (Romania)

Marek Jutel (Poland)

Oscar Palomares (Spain)

SYM 01 Novel insights into the development of allergic disease

Saturday, 6 June 2020 - 10:45-12:15 CET

Learning objectives:

- To discuss the properties of allergen and their role in allergy sensitization.
- To discuss novel insights into development of allergic diseases.
- To discuss and outline the role of the epithelium in allergic diseases.
- To discuss the impact of multiple stressors through different environmental pathways and their impact on Allergy.
- To discuss the impact of pollution on allergic diseases and outline call for actions.

How do allergens sensitize?

Barbara Bohle (Austria)

Novel insight into development of allergic diseases

Jean Bousquet (France)

Epithelial cell barrier and allergic diseases

Cezmi Akdis (Switzerland)

Lifelong exposure to multiple stressors through different environmental pathways and their impact on allergy

Isabella Annesi-Maesano (France)

Air pollution and allergy: call for action!

Stephen Holgate (United Kingdom)

Q&A

Programme description

Saturday, 6 June 2020

SYM 02 Food allergy: prevention is better than cure

Saturday, 6 June 2020 - 12:45-14:15 CET

Learning objectives:

- To provide an update on current strategies of prevention of food allergy.
- To gain insight into issues that families have to implement these recommendations.
- To discuss therapeutic approaches to prevent food allergy derived from weaning products.
- To discuss the role of gut microbiota in development of food allergy and the use of synbiotics in the management of food allergy.
- To discuss the dietary and psychological issues observed in the allergy clinic related early to food introductions.

Prevention of food allergy: where are we now?

Gideon Lack (United Kingdom)

Challenges on the implementation of early introduction of allergenic foods

Edmond S. Chan (Canada)

Over-the-counter allergy prevention weaning products

Michael Perkin (United Kingdom)

Latest developments in pre, pro and synbiotics in food allergy prevention

Nikolaos Papadopoulos (Greece)

Dietary and psychological issues related to food introductions

Carina Venter (United States)

Q&A

SYM 03 Biologicals and other therapies in allergy: from clinical trials to clinical practice

Saturday, 6 June 2020 - 14:45-16:15 CET

Learning objectives:

- To discuss and give evidence of anti-TSLP in severe uncontrolled asthma.
- To discuss and give evidence of anti-IL4Ra in atopic dermatitis.
- To discuss and give evidence of anti-IgE in chronic spontaneous urticaria.
- To discuss interferon therapy as an asthma preventative treatment approach.
- To discuss novel developments in biosimilars and drug development in Allergy.

Tezepelumab (anti-TSLP) in asthma

Jonathan Corren (United States)

Dupilumab (anti-IL4Ra) in CRSwNP

Claus Bachert (Belgium)

Ligelizumab (anti-IgE) in chronic spontaneous urticaria

Marcus Maurer (Germany)

Interferon therapy and novel biologicals

Sebastian Lennox Johnston (United Kingdom)

Upcoming drug developments and biosimilars

Matteo Bonini (Italy)

Q&A

Programme description

Saturday, 6 June 2020

SSS 01 EAACI - NIAID/NIH Joint Symposium:
From bench to bedside: Potential therapeutics for allergic diseases from the NIAID-supported Asthma and Allergic Diseases Cooperative Research Centers
Saturday, 6 June 2020 - 16:45-17:45 CET

Learning objectives:

- To discuss how to target Rhinovirus for asthma prevention.
- To discuss the utility of Glucagon-like-1 receptor agonist in asthma.
- To describe the therapeutic opportunities of Siglecs.

Targeting rhinovirus infection as a strategy for asthma prevention and treatment
James E Gern (United States)

Glucagon-like 1 receptor agonists: repurposing for asthma?
Ray Stokes Peebles, Jr. (United States)

Siglecs on eosinophils and mast cells: from biology to therapeutic opportunities
Bruce Scott Bochner (United States)

Q&A

Welcome Ceremony

Saturday, 6 June 2020 - 19:50-20:00 CET

OKS 1 The EAACI Congress 2020 opening Keynote Symposia: Solutions and challenges in modern medicine

Saturday, 6 June 2020 - 20:00-21:00 CET

Learning objectives:

- To describe the journey of biologicals in modern medicine.
- To describe and outline the impact of COVID-19 in health and respiratory airway disease.
- Immune modulation strategy in the management of COVID-19.

Chairs

Mohamed Shamji (United Kingdom), Marek Jutel (Poland)

Paving the way for biologicals in modern medicine (The Nobel Laureate Keynote Lecture)
Gregory Winter (United Kingdom)

Corona virus and lung inflammation - the current pandemic
Peter Openshaw (United Kingdom)

Immune modulation in the era of COVID19
Marek Jutel (Poland)

EAACI Awards

Saturday, 6 June 2020 - 20:50-21:05 CET



SSS 02 EAACI – ACAAI joint symposium:
Atopic dermatitis: what's new?
Saturday, 6 June 2020 - 18:15-19:15 CET

Learning objectives:

- To discuss how to use the atopic Dermatitis Yardstick in the clinic.
- To discuss how to manage atopic dermatitis.
- To describe the novel therapeutic approaches in atopic dermatitis.

Using the “atopic dermatitis yardstick” in clinical practice
James L Sublett (United States)

Managing quality of life and comorbidity issues in atopic dermatitis
Michael S. Blaiss (United States)

JAK inhibitors and monoclonals: the future of atopic dermatitis management
Luz Fonacier (United States)

Q&A



FAAM 2020
15 – 17 October 2020
Manchester, United Kingdom



Food Allergy and Anaphylaxis Meeting



www.eaaci.org



Programme at a Glance



Sunday, 7 June 2020

This page gives an overview of the digital sessions organised on June 7, 2020. The original scientific programme created for the EAACI Congress 2020 in London includes much more content. It is possible to access this "Recorded Scientific Programme" by clicking on the link button on the right.

Recorded Scientific Programme

CET Time	Track 1 Live Scientific Programme	Track 2 Industry Programme	
09:00	09:00 - 10:20 CET KS 2 - Keynote Symposia Novel insights into Immunotherapy approaches for food and aeroallergens		
09:15			
09:30			
09:45			
10:00			
10:15			
10:30	Digital break		
10:45	10:45 - 11:45 CET SSS 3 - Sister Society Symposium EAACI - APAAACI joint symposium: allergies in asia pacific: insights and lessons learnt east versus west	10:30 - 11:45 CET CSS 7 - Company Sponsored Symposia	
11:00			
11:15			
11:30			
11:45			
12:00	Digital break		
12:15	12:15 - 13:45 CET SYM 4 - Symposia Utility of OMICs: a roadmap to precision medicine	12:00 - 13:15 CET CSS 8 - Company Sponsored Symposia	
12:30			
12:45			
13:00			
13:15			
13:30		13:30 - 14:00 CET CSS 9 - Company Sponsored Symposia	
13:45	Digital break		
14:00			
14:15	14:15 - 15:15 CET SSS 4 - Sister Society Symposium EAACI - ERS joint symposium: asthma for the roaring 20-twenties		
14:30			
14:45			
15:00			
15:15			
15:30	Digital break	15:00 - 16:15 CET CSS 10 - Company Sponsored Symposia	
15:45			
16:00	15:45-17:15 CET SYM 5 - Symposia Insights into the management of drug allergy		
16:15			
16:30			
16:45			
17:00		16:30 - 17:45 CET CSS 11 - Company Sponsored Symposia	
17:15	Digital break		
17:30			
17:45	17:45-19:15 CET SYM 6 - Symposia Novel mechanisms in united severe united airway disease		
18:00			
18:15			
18:30			
18:45	18:00 - 19:15 CET CSS 12 - Company Sponsored Symposia		
19:00			
19:15			
19:30			
19:45			
20:00			
20:15			
20:30			
20:45			
21:00			
21:15			

Programme description



Sunday, 7 June 2020

KS 2 Novel insights into Immunotherapy approaches for food and aeroallergens

Sunday, 7 June 2020 - 09:00-10:20 CET

Learning objectives:

- To describe endotypes of upper airway disease and discuss the clinical effectiveness of novel biologics that target endotypes.
- To describe new emerging approaches in immunotherapy for inhalant allergens.
- To discuss the utility of artificial intelligence (machine learning) in biomarker discovery for immunotherapy.

Chairs

Cezmi Akdis (Switzerland), Stephen R Durham (United Kingdom)

Immunotherapy for food allergy: is tolerance too much of an expectation? - Q&A

George du Toit (United Kingdom)

Mechanisms of Oral, SLIT and other approaches of food immunotherapy - Q&A

Wayne G Shreffler (United States)

B cell tolerance: an essential mechanism for allergen immunotherapy in house dust mite allergy - Q&A

Mübeccel Akdis (Switzerland)

Artificial intelligence approach to understanding the mechanisms and biomarker discovery for allergen immunotherapy - Q&A

Mohamed Shamji (United Kingdom)

SSS 03 EAACI - APAAACI joint symposium: Allergies in asia pacific: insights and lessons learnt east versus west

Sunday, 7 June 2020 - 10:45-11:45 CET

Learning objectives:

- To describe house dust mite allergy in Asia Pacific.
- To highlight aspects of allergic diseases in Asia Pacific and the similarities and differences between east and west, specifically lifestyles, cultural and socio-economics, as well as changing environments and lifestyles and growing economies.
- To discuss the burden and consensus on urticaria management in Asia Pacific.

House dust mite allergy in Asia Pacific

Jiu-Yao Wang (Taiwan)

Climate change and air pollution in Asia Pacific and impact on respiratory allergy

Ruby Pawankar (Japan)

Burden and consensus on urticaria management in Asia Pacific

Amir Hamzah Abdul Latiff (Malaysia)

Q&A



Programme description



Sunday, 7 June 2020

SYM 04 Utility of OMICs: a roadmap to precision medicine

Sunday, 7 June 2020 - 12:15-13:45 CET

Learning objectives:

- To discuss the novel computational models and current challenges.
- To discuss the OMICs data integration in allergy.
- To describe novel approaches to visualize and track tissue inflammation.
- To outline the advantages and disadvantages of untargeted and targeted metabolomics in phenotyping allergic diseases novel approaches to visualize and track tissue inflammation.
- The utility of system biology approaches to advance clinical patient care.

Human and computational models of immune mediated inflammatory skin disease: challenges, insights and perspectives

Nick Reynolds (United Kingdom)

Integrative OMICs data analysis reveals key drivers of peanut allergic reactions

Kari Christine Nadeau (United States)

Utility of single-cell RNA sequencing to identify distinct gene signature in airway Th2 cells

Jonathan Coquet (Sweden)

Utility of untargeted and targeted metabolomic approaches in phenotyping allergic diseases

Domingo Barber (Spain)

Integrated systems biology strategies for diagnostics and immune monitoring in allergy

Markus Ollert (Luxembourg)

Q&A

SSS 04 EAACI - ERS joint symposium:

Asthma for the roaring 20-twenties

Sunday, 7 June 2020 - 14:15-15:15 CET

Learning Objectives:

- To provide an update on the big changes in asthma treatment: GINA 2019.
- To discuss the role of personalized medicine in severe asthma in low- and middle-income countries.
- To describe novel approaches to childhood asthma.

Big changes in asthma treatment : GINA 2019

Luis Pérez de Llano (Spain)

Tailored therapy in severe asthma: is it a dream in low- and middle-income countries?

Arzu Yorgancioglu (Turkey)

A system biology and machine learning approach to childhood asthma

Adnan Custovic (United Kingdom)

Q&A

Programme description



Sunday, 7 June 2020

SYM 05 Insights into the management of drug allergy

Sunday, 7 June 2020 - 15:45-17:15 CET

Learning objectives:

- To describe the differences in management of NSAID hypersensitivity in children and adults.
- To discuss the management of drug reactions in a perioperative setting.
- To discuss the management of drug reactions in a perioperative setting.
- To describe the management of adverse reactions to biologics.

NSAID hypersensitivity of children vs adults

Marina Atanaskovic-Markovic (Serbia)

Drug reactions in the perioperative setting

Lene Heise Garvey (Denmark)

Early biomarkers for severe drug hypersensitivity reactions

Maria J Torres (Spain)

Management of adverse reactions to biologics

Mariana Castells (United States)

Utility of provocation tests before deciding to desensitize

Jean-Christoph Caubet (Switzerland)

Q&A

SYM 06 Novel mechanisms in united severe airway disease

Sunday, 7 June 2020 - 17:45-19:15 CET

Learning objectives:

- To describe the relationship between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis.
- To describe novel insights in innate lymphoid cells in upper and lower airway disease and how they can be exploited for therapeutic use.
- To discuss the pathogenic and protective role of B cells in Chronic Rhinosinusitis.
- To discuss recent advances in genomics in severe airway disease.
- To describe and discuss the clinical effectiveness of novel biologics that target endotypes.

Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis

Atsushi Kato (United States)

Targeting innate lymphoid cells in lower and upper airway disease: what's new?

Hideaki Morita (Japan)

B cells in chronic rhinosinusitis: friend or foe

Anju Tripathi Peters (United States)

Advances in genomics in severe airway disease

Sanna Toppila-Salmi (Finland)

Novel therapeutic approaches targeting endotypes of severe airway disease

Philippe Gevaert (Belgium)

Q&A



DHM 2021

Spring 2021
Verona, Italy



Drug Hypersensitivity Meeting

Programme at a Glance

Monday, 8 June 2020

This page gives an overview of the digital sessions organised on June 7, 2020. The original scientific programme created for the EAACI Congress 2020 in London includes much more content. It is possible to access this "Recorded Scientific Programme" by clicking on the link button on the right.



Recorded Scientific
Programme

CET
Time

Track 1
Live Scientific Programme

Track 2
Industry Programme

09:00

09:15

09:30

09:45

10:00

10:15

10:30

10:45

11:00

11:15

11:30

11:45

12:00

12:15

12:30

12:45

13:00

13:15

13:30

13:45

14:00

14:15

14:30

14:45

15:00

15:15

15:30

15:45

16:00

16:15

16:30

16:45

17:00

17:15

17:30

17:45

18:00

18:15

18:30

18:45

19:00

19:15

19:30

19:45

20:00

20:15

20:30

20:45

21:00

21:15

09:00 - 10:20 CET
KS 3 - Keynote Symposia
Trained innate immunity and therapeutic target
of immune-mediated disease

Digital break

10:45 - 12:15 CET
SYM 7 - Symposia
Targeting the skin immune response for disease
prevention and control

Digital break

12:45 - 14:15 CET
SYM 8 - Symposia
Targeting the microbiome for clinical care

Digital break

14:45 - 16:15 CET
SYM 9 - Symposia
Allergen immunotherapy: outcome measures, mechanisms
and biomarkers

Digital break

16:45 - 17:45 CET
SSS 5 - Sister Society Symposium
WAO joint symposium: World allergy forum: impact of climate
change on allergic diseases

Digital break

18:15 - 19:15 CET
SSS 6 - Sister Society Symposium
EAACI - AAAAI joint symposium: a new era in asthma
management: perspectives from the United States

19:15 - 19:30 CET Closing Ceremony

12:00 - 13:15 CET
CSS14 - Company Sponsored Symposia

18:00 - 19:15 CET
CSS 17 - Company Sponsored Symposia

EAACI.org



EAACI Digital Congress
2020 6-8 June

Programme description



Monday, 8 June 2020

KS 3 Trained innate immunity and therapeutic target of immune-mediated disease

Monday, 8 June 2020 - 09:00-10:20 CET

Learning objectives:

- To discuss immunologic response in cancer.
- To describe and discuss the effect of exposome on epithelial dysregulation as a driving effect on asthma development.
- To discuss how to target immune mechanisms and prevent asthma development.
- To describe and discuss the role of neutrophil dysfunction in immune deficiency.

Chairs

Jürgen Schwarze (United Kingdom),
Karin Hoffmann-Sommergruber (Austria)

Trained innate immunity and regulation of inflammation by interleukin-1 related cytokines - Q&A

Alberto Mantovani (Italy)

Epithelial cell dysfunction, a major driver of asthma development - Q&A

Irene Heijink (The Netherlands)

Targeting immune pathways in early-life for asthma prevention - Q&A

Clare M Lloyd (United Kingdom)

Neutrophil dysfunction - beyond immune deficiency - Q&A

Isabelle Meyts (Belgium)

SYM 07 Targeting the skin immune response for disease prevention and control

Monday, 8 June 2020 - 10:45-12:15 CET

Learning objectives:

- To discuss the effect of the exposome in atopic dermatitis.
- To discuss the importance of biomarkers immunophenotyping of atopic dermatitis.
- To discuss the importance of skin care from birth in allergy prevention.
- To discuss the novel therapeutic targets and strategies in atopic dermatitis.
- To discuss state-of-the art patient management in preventing Hereditary Angioedema attacks.

Impact of the exposome in atopic dermatitis

Alan Irvine (Ireland)

Implementing biomarkers in immunophenotyping of atopic dermatitis

Edward Frank Knol (The Netherlands)

Skin care from birth for allergy prevention: results today

Helen A Brough (United Kingdom)

Novel targets for treatment in atopic dermatitis

Emma Guttman Yassky (United States)

Hereditary angioedema – the best way to prevent attacks

Clive Grattan (United Kingdom)

Q&A

Programme description



Monday, 8 June 2020

SYM 08 Targeting the microbiome for clinical care

Monday, 8 June 2020 - 12:45-14:15 CET

Learning objectives:

- To review how the microbiome modifies Immune Endotypes in Allergic Diseases.
- To describe the clinical applications of microbiome in allergy and cancer immunotherapy.
- To discuss the link between gut microbiome and the development of allergic diseases.
- To describe how antibiotics can alter the microbiome and modulate allergic inflammation in asthmatics the current knowledge on how microbiota modulate immune response and support immunotherapy.
- To describe the current knowledge on how microbiota modulate immune response and support immunotherapy.

Microbiome and the immune response:

A clinical perspective

Eva Untersmayr (Austria)

Living environment-dependent modification of immune endotypes in allergic diseases

Nonhlanhla Lunjani (Ireland)

Gut microbiome and the development of food allergy and allergic disease

Anne Marie Singh (United States)

Gut microbiome and histamine signal in pathogenesis of IBD

Sylwia Smolinska (Poland)

Gut microbiome - based therapeutic approaches

Liam O'Mahony (Ireland)

Q&A

SYM 09 Allergen immunotherapy: outcome measures, mechanisms and biomarkers

Monday, 8 June 2020 - 14:45-16:15 CET

Learning objectives:

- To discuss the current approaches of allergen immunotherapy using in vivo allergen challenges.
- To describe the different approaches of monitoring clinical response following immunotherapy in adults and children.
- To describe the mechanisms and importance of T cell tolerance in allergen immunotherapy.
- To describe the relevance of B cell modulation in tolerance induction during immunotherapy.
- To describe immune monitoring biomarkers of immunotherapy.

Allergen immunotherapy: nasal allergen vs chamber challenges vs other tests

Stephen R Durham (United Kingdom)

Outcome measures for adult's vs children in the clinic during allergen immunotherapy

Constantinos Pitsios (Cyprus)

T cell tolerance during allergen immunotherapy

Erik R Wambre (United States)

Benefit, risk ratio and improving oral allergen immunotherapy

Paul J Turner (United Kingdom)

Molecular immune biomarkers for protein-based and peptide immunotherapy

Mark Larché (Canada)

Q&A

Programme description

Monday, 8 June 2020

SSS 05 EAACI – WAO joint symposium: World allergy forum: impact of climate change on allergic diseases

Monday, 8 June 2020 - 16:45-17:45 CET

Learning objectives:

- To describe current understanding of how the environment is changing.
- To identify the effects on the immune system and allergic diseases such as allergic rhinitis and asthma.
- To evaluate environment-based and pharmacologic interventions.

Impact of climate change on the immune system

David B. Peden (United States)

International expert consensus on the management of allergic rhinitis aggravated by air pollutants

Philip Wakim Rouadi (Lebanon)

Impact of climate change on asthma exacerbations

Sandra Nora González Díaz (Mexico)

Q&A

Closing ceremony

Monday, 8 June 2020 - 19:15-19:30 CET

Presidential message & 2021 EAACI Congress announcement

SSS 06 EAACI - AAAAI joint symposium: A new era in asthma management: perspectives from the United States

Monday, 8 June 2020 - 18:15-19:15 CET

Learning Objectives:

- To demonstrate a personalized approach to the selection of a biologic agent for a patient with severe asthma.
- To discuss the current level of evidence on allergen abatement in asthma management.
- To describe differences in asthma guidelines.

Personalized asthma care - the use of biologics

Thomas Casale (United States)

Allergen abatement: the impact of environmental interventions in different patient populations

Wanda Phipatanakul (United States)

Reconciling differences in asthma guidelines

Leonard Bacharier (United States)

Q&A



SAM 2021

11 – 13 March 2021
Copenhagen, Denmark



Skin Allergy Meeting

Joint meeting



EAACI.org



Speaker index



This page gives an index of all the **speakers of the Live Scientific Programme**. The original scientific programme created for the EAACI Congress 2020 in London includes much more content and speakers. It is possible to access this "Recorded Scientific Programme" by clicking on the link button on the right.

Recorded Scientific Programme

Speaker name	Country	Symposium
Adnan Custovic	United Kingdom	June 7, SSS 4
Alan Irvine	Ireland	June 8, SYM 7
Alberto Mantovani	Italy	June 8, KS 3
Amir Hamzah Abdul Latiff	Malaysia	June 7, SSS 3
Anju Tripathi Peters	United States	June 7, SYM 6
Anne Marie Singh	United States	June 8, SYM 8
Arzu Yorgancioglu	Turkey	June 7, SSS 4
Atsushi Kato	United States	June 7, SYM 6
Barbara Bohle	Austria	June 6, SYM 1
Benjamin Marsland	Australia	June 6, KS 1
Bruce Scott Bochner	United States	June 6, SSS 1
Carina Venter	United States	June 6, SYM 2
Cezmi Akdis	Switzerland	June 6, SYM 1
Clare M Lloyd	United Kingdom	June 8, KS 3
Claus Bachert	Belgium	June 6, SYM 3
Clive Grattan	United Kingdom	June 8, SYM 7
Constantinos Pitsios	Cyprus	June 8, SYM 9
David B. Peden	United States	June 8, SSS 5
Domingo Barber	Spain	June 7, SYM 4
Edmond S. Chan	Canada	June 6, SYM 2
Edward Frank Knol	The Netherlands	June 8, SYM 7
Emma Guttman Yassky	United States	June 8, SYM 7
Erik R Wambre	United States	June 8, SYM 9
Eva Untersmayr	Austria	June 8, SYM 8
George du Toit	United Kingdom	June 7, KS 2
Gideon Lack	United Kingdom	June 6, SYM 2
Gregory Winter	United Kingdom	June 6, OKS 1
Helen A Brough	United Kingdom	June 8, SYM 7
Hideaki Morita	Japan	June 7, SYM 6
Ioana Octavia Agache	Romania	June 6, KS 1
Irene Heijink	The Netherlands	June 8, KS 3
Isabella Annesi-Maesano	France	June 6, SYM 1
Isabelle Meyts	Belgium	June 8, KS3
James E Gern	United States	June 6, SSS 1
James L Sublett	United States	June 6, SSS 2
Jean Bousquet	France	June 6, SYM 1
Jean-Christoph Caubet	Switzerland	June 7, SYM 5
Jiu-Yao Wang	Taiwan	June 7, SSS 3
Jonathan Coquet	Sweden	June 7, SYM 4
Jonathan Corren	United States	June 6, SYM 3

Speaker index



This page gives an index of all the **speakers of the Live Scientific Programme**. The original scientific programme created for the EAACI Congress 2020 in London includes much more content and speakers. It is possible to access this "Recorded Scientific Programme" by clicking on the link button on the right.

Recorded Scientific Programme

Speaker name	Country	Symposium
Kari Christine Nadeau	United States	June 7, SYM 4
Kian Fan Chung	United Kingdom	June 6, KS 1
Lene Heise Garvey	Denmark	June 7, SYM 5
Leonard Bacharier	United States	June 8, SSS 6
Liam O'Mahony	Ireland	June 8, SYM 8
Luis Pérez de Llano	Spain	June 7, SSS4
Luz Fonacier	United States	June 6, SSS 2
Marcus Maurer	Germany	June 6, SYM 3
Marek Jutel	Poland	June 6, KS 1 & OKS 1
Maria J Torres	Spain)	June 7, SYM 5
Mariana Castells	United States	June 7, SYM 5
Marina Atanaskovic-Markovic	Serbia	June 7, SYM 5
Mark Larché	Canada	June 8, SYM 9
Markus Ollert	Luxembourg)	June 7, SYM 4
Matteo Bonini	Italy)	June 6, SYM 3
Michael Perkin	United Kingdom	June 6, SYM 2
Michael S. Blaiss	United States	June 6, SSS 2
Mohamed Shamji	United Kingdom	June 7, KS 2
Mübeccel Akdis	Switzerland	June 7, KS 2
Nick Reynolds	United Kingdom	June 7, SYM 4
Nikolaos Papadopoulos	Greece	June 6, SYM 2
Nonhlanhla Lunjani	Ireland	June 8, SYM 8
Oscar Palomares	Spain	June 6, KS 1
Patrick Holt	Australia	June 6, KS 1
Paul J Turner	United Kingdom	June 8, SYM 9
Peter Openshaw	United Kingdom	June 6, OKS 1
Philip Wakim Rouadi	Lebanon	June 8, SSS 5
Philippe Gevaert	Belgium	June 7, SYM 6
Ray Stokes Peebles, Jr.	United States	June 6, SSS1
Ruby Pawankar	Japan	June 7, SSS3
Sandra Nora González Díaz	Mexico	June 8, SSS5
Sanna Toppila-Salmi	Finland	June 7, SYM 6
Sebastian Lennox Johnston	United Kingdom	June 6, SYM 3
Stephen Holgate	United Kingdom	June 6, SYM 1
Stephen R Durham	United Kingdom	June 8, SYM 9
Sylwia Smolinska	Poland	June 8, SYM 8
Thomas Casale	United States	June 8, SSS 6
Wanda Phipatanakul	United States	June 8, SSS 6
Wayne G Shreffler	United States	June 7, KS 2



National Society Village



The National Allergy Society Village is open throughout the entire Digital Congress and features the virtual booths of our NAS from all over Europe. At each booth you will be able to visualise brochures, watch videos, consult important national resources and much more. You will also have the chance to interact with respective members of the NAS through an e-mail form.

We encourage you to visit this area to learn more about your country's very own society dedicated to allergy, asthma and immunology, or explore developments in the field from other countries.



Belgium

Association Belge de Formation Continue en Allergologie



Greece

Greek Pediatric Allergy Society



Greece

Hellenic Society of Allergology and Clinical Immunology



Italy

Italian Society of Allergology, Asthma and Clinical Immunology



Italy

Italian Association of Hospital and Territorial Allergists and Immunologists



Italy

Societatea Romana de Pneumologie



North Macedonia

Society of Pulmonologists of the Republic of Macedonia



Latin America

Sociedad Latino Americana de Alergia, Asma e Inmunologia - Slaai



Poland

Polish Society of Allergology



Romania

Romanian Society of Pneumology



Serbia

Serbian Association for Allergology and Clinical Immunology



Turkey

Turkish Academy of Pediatric Allergy and Asthma



Turkey

Turkish National Society of Allergy and Clinical Immunology



Turkey

Turkish Society of Immunology TSI/ EFIS



Turkey

Turkish Thoracic Society



United Kingdom

The British Society for Allergy and Clinical Immunology - BSACI



Asia Pacific

Asia Pacific Academy of Pediatric Allergy, Respiriology and Immunology - APAPARI



Asia Pacific

Asia Pacific Association of Allergy Asthma and Clinical Immunology - ACAAI



European Academy of Allergy
and Clinical Immunology
19-23 June 2021
MADRID



EAACI Congress 2021



[EAACI.org](https://eaaci.org)

[#eaaci2021](https://twitter.com/eaaci2021)



EAACI Digital Congress
2020 6-8 June

Sponsorship and Exhibition

This section contains information that is promotional in nature, distinct from the scientific /educational elements of the EAACI Digital Congress 2020.



Novartis Company-
Sponsored Symposium

Targeting IgE: what does it mean for patients, especially during this COVID-19 crisis?

We are pleased to invite you to this Novartis-sponsored virtual symposium, where leading clinicians will discuss perspectives and new findings on asthma, comorbidities and chronic spontaneous urticaria management. The panel will share their experience of how COVID-19 impacts their daily practice, and the consequences for management of patients with these IgE-mediated diseases. Targeting IgE, what does it mean for your patients, especially during the COVID-19 crisis?

Symposium will be streamed at
EAACI 2020 Congress on
Saturday 6 June 2020

13:30–14:45 CEST
Available on demand thereafter

Agenda

Chaired by Nikos Papadopoulos

Welcome and Introduction
What have we learned from the COVID-19 crisis?




Perspectives and new findings on asthma and comorbidity
management: what to EXPECT



Omalizumab in chronic spontaneous urticaria, be AWARE



Roundtable discussion



NOVARTIS | Reimagining Medicine

This symposium may include discussion either on investigational products or those not approved by regulatory authorities in your country. Physicians may only prescribe products in accordance with their prescribing information. Prescribing information differs from country to country. Please refer to your local prescribing information.

This symposium is organised and funded by Novartis Pharma AG. This meeting is intended for healthcare professional
© Novartis Pharma AG May 2020 | CH-4002 Basel, Switzerland | GLRESP/RESP/0391e | May 2020.

Founder Sponsors



EAACI and the Local Organising Committee gratefully acknowledge the support of the 2020 Founder Sponsors.

Platinum Founder Sponsors EAACI Digital Congress 2020

**Allergy
Therapeutics**

AstraZeneca



NOVARTIS | Reimagining Medicine

SANOFI GENZYME
REGENERON

STALLERGENES **GREER**
Life beyond allergy

Gold Founder Sponsor EAACI Digital Congress 2020

allergopharma

Silver Founder Sponsor EAACI Digital Congress 2020

LETIPharma
Since 1919

Please [click here](#) to view the full list of the EAACI Founder Sponsors.



Dedicated to improving the lives of patients and families with food allergies

DBV is focused on discovering safe and effective treatments for patients with food allergies and other immunological diseases.



Company Sponsored Symposia

Saturday, 6 June 2020

COMPANY SPONSORED SYMPOSIUM (CSS 1)

Sanofi Genzyme / Regeneron: Type 2 Inflammation in Atopic Dermatitis and Beyond: Shared Pathophysiology and Clinical Management

Saturday, 6 June 2020 - 10.30-11.45 CET

Welcome and Introduction

Marcus Maurer, Germany

Shared Pathophysiology and Epidemiology of Atopic Dermatitis with Other Type 2 Inflammatory Diseases

Marcus Maurer, Germany

Clinical Management of Atopic Dermatitis and Other Type 2 Inflammatory Diseases

Miriam Wittmann, United Kingdom

Panel Q&A

All faculty

COMPANY SPONSORED SYMPOSIUM (CSS 3)

Novartis Pharma AG: Targeting IgE: what does it mean for patients, especially during this COVID-19 crisis?

Saturday, 6 June 2020 - 13.30-14.45 CET

Chair: Nikolaos Papadopoulos, United Kingdom

Welcome and Introduction: What we have learned from the COVID-19 crisis?

Nikolaos Papadopoulos, United Kingdom

Perspectives and new findings on asthma and comorbidity management: what to EXPECT

Marc Humbert, France

Q&A

Nikolaos Papadopoulos, United Kingdom

Marc Humbert, France

Omalizumab in chronic spontaneous urticaria, be AWARE

Ana Maria Giménez-Arnau, Spain

Roundtable discussion

All faculty



COMPANY SPONSORED SYMPOSIUM (CSS 2)

MSD: Chronic Cough; What Allergists Need to Know

Saturday, 6 June 2020 - 12.00-13.15 CET

Chair: Joaquin Sastre, Spain

Welcome and Opening Remarks: Chronic cough and the allergist

Joaquin Sastre, Spain

What is the mechanism of chronic cough and the burden on patients and their subsequent journey through the Healthcare System?

Jaclyn Ann Smith, United Kingdom

What are the main causes of chronic cough and how to best diagnose and treat them

Michael Blaiss, United States

Q&A via Chat

All faculty

COMPANY SPONSORED SYMPOSIUM (CSS 5)

Sanofi Genzyme / Regeneron: Dupilumab: Bridging Innovation in Biologic Treatment Across Type 2 Inflammatory Airway Diseases

Saturday, 6 June 2020 - 16.30-17.45 CET

Chair: William W. Busse, United States

Opening Remarks: Type 2 Inflammation in Airway Disease

William W. Busse, United States

Clinical Trial Evidence for Dupilumab in Patients With CRSwNP

Claus Bachert, Belgium

Patient Selection and Management Approaches in CRSwNP

Claus Bachert, Belgium

Dupilumab Clinical Insights in Type 2 Inflammatory Airway Diseases

Raffi Tachdjian, United States

Closing Remarks

William W. Busse, United States

VISIT OUR VIRTUAL BOOTH TO
CHAT AND DISCOVER MORE

3 INDICATIONS

2 KEY CYTOKINES

1 BIOLOGIC

Please see copy of the full European SmPC and Abbreviated Swiss Indication Statement at the Sanofi Genzyme and Regeneron Digital booths at EAACI Digital Congress 2020. In Switzerland, some specific Sanofi Genzyme and Regeneron products are only approved for the treatment of Atopic Dermatitis in Adults.

Sanofi Genzyme and Regeneron does not recommend or intend for any of its products to be used in a manner which may be inconsistent with approved product labelling.



Company Sponsored Symposia

Sunday, 7 June 2020

COMPANY SPONSORED SYMPOSIUM (CSS 7)
Nestlé Health Science: New Advances in the Prevention and Management of Food Allergy
Sunday, 7 June 2020 - 10.30-11.45 CET

Chair: Yvan Vandenplas, Belgium

Nutritional Strategies for Food Allergy Prevention
Carina Venter, United States

Human Milk Oligosaccharides (HMO) for the Immune System Development
Norbert Sprenger, Switzerland

New data on the Benefits of HMO in the Management of Cow's Milk Protein Allergy
Anna Nowak-Węrzyn, United States

COMPANY SPONSORED SYMPOSIUM (CSS 9)
Sanofi Genzyme / Regeneron: Scoping CRSwNP: Putting the Spotlight on Type 2 Inflammation
Sunday, 7 June 2020 - 13.30-14.00 CET

Chair: Peter Hellings, Belgium

Evaluating CRSwNP Burden: A Closer Look at the Patient Experience
Peter Hellings, Belgium

Type 2 Inflammation as the Key Driver of CRSwNP Pathophysiology
Peter Hellings, Belgium

Treating CRSwNP: Evolving the Therapeutic Space With Biologics
Claus Bachert, Belgium

COMPANY SPONSORED SYMPOSIUM (CSS 8)
DBV TECHNOLOGIES: Life with Peanut allergy: What is the potential role of investigational Viaskin Peanut?
Sunday, 7 June 2020 - 12.00-13.15 CET

Chairs:
Helen Brough, United Kingdom
Susanne Lau, Germany

Introduction
Susanne Lau, Germany

The psycho-social impact of peanut allergy for children and their families
Antonella Muraro, Italy

Can the increase in threshold of eliciting doses help peanut allergic subjects?
Graham Roberts, United Kingdom

Investigational Viaskin Peanut clinical trial data: efficacy, safety, practicality
Lars Lange, Germany

Conclusion
Helen Brough, United Kingdom

COMPANY SPONSORED SYMPOSIUM (CSS 10)
STALLERGENES GREER: Overcoming challenges in 2020: Bringing a positive outlook to allergic patients' horizons
Sunday, 7 June 2020 - 15.00-16.15 CET

Chair: Ludger Klimek, Germany

COVID-19 Pandemic: AIT positioning in respiratory allergy
Walter Canonica, Italy

Childhood AR and Asthma and development patterns of lung function
Adnan Custovic, United Kingdom

Shaping the horizons of allergic patients
Philippe Gevaert, Belgium

Expert panel discussion - Q&A Chat



Transforming Allergy Lives Allergy Therapeutics

Experience our new look at the Virtual Exhibition of the EAACI Digital Congress 2020.

Join us to learn more on how Ultra-short Course Allergen Immunotherapy is transforming lives

Allergy Therapeutics

Bencard Allergie





Sunday, 7 June 2020

COMPANY SPONSORED SYMPOSIUM (CSS 11)

GSK: Mepolizumab: Targeting eosinophils in children and adults with severe eosinophilic asthma (SEA)

Sunday, 7 June 2020 - 16.30-17.45 CET

Chair: Neil Martin, United Kingdom

Welcome address from chair

Neil Martin, United Kingdom

An expert view of SEA in patients of all ages

Peter Gibson, Australia

Latest mepolizumab data: Long-term and real-world evidence in adults

Stephanie Korn, Germany

Building on the foundation of mepolizumab: Data in paediatric patients

Atul Gupta, United Kingdom

Expert opinion: Clinical cases in patients with SEA

Liam Heaney, United Kingdom

Peter Gibson, Australia

Stephanie Korn, Germany

Atul Gupta, United Kingdom

Neil Martin, United Kingdom

Closing remarks

Neil Martin, United Kingdom

Live chat Q&A

All faculty

COMPANY SPONSORED SYMPOSIUM (CSS 12)

Sanofi Genzyme / Regeneron: Type 2 Inflammation and Role of Key Mediators in the Clinical Hallmarks of Uncontrolled Severe Asthma

Sunday, 7 June 2020 - 18.00-19.15 CET

Chair: Leonard B. Bacharier, United States

Welcome and Opening Remarks

Leonard B. Bacharier, United States

Michael Wechsler, United States

Defining Control and Type 2 Inflammation in Severe Asthma

Michael Wechsler, United States

Elucidating the Roles Key Cytokines Play in Clinical Manifestations of Severe Asthma

Leonard B. Bacharier, United States

Applying Understanding of Type 2 Inflammation in Clinical Practice

All faculty

Closing / Q&A

All faculty

STALLERGENES GREER DIGITAL SYMPOSIUM 2020

OVERCOMING CHALLENGES IN 2020:

BRINGING A POSITIVE OUTLOOK TO ALLERGIC PATIENTS' HORIZONS

Introduction by Chair (5 minutes)

- L. Klimek (Germany)

Presentations (20 minutes each)

- COVID-19 Pandemic: AIT positioning in respiratory allergy
G.W. Canonica (Italy)
- Childhood AR and asthma and development patterns of lung function
A. Custovic (United Kingdom)
- Shaping the horizons of allergic patients
P. Gevaert (Belgium)
- Q&A

Sunday 7 June 2020 | 15:00 – 16:15

YOU CAN ALSO VISIT OUR BOOTH IN THE DIGITAL EXHIBITION HALL, WHERE WE ARE FOCUSING ON SHAPING THE HORIZONS OF ALLERGIC PATIENTS.



Company Sponsored Symposia

Monday, 8 June 2020

COMPANY SPONSORED SYMPOSIUM (CSS 14)
Novartis Pharma AG: Breakthrough in the understanding of the anti-IgE pathway in CSU
Monday, 8 June 2020 - 12.00-13.15 CET

Chairs:
Marcus Maurer, Germany
Alexander Eggel, Switzerland

Introduction to CSU
Marcus Maurer, Germany

IgE inhibition in CSU: Not all anti-IgEs are born equal
Alexander Eggel, Switzerland

IgE inhibition implications: How does this benefit patients with CSU?
Marcus Maurer, Germany

Q&A
Marcus Maurer, Germany
Alexander Eggel, Switzerland

COMPANY SPONSORED SYMPOSIUM (CSS 17)
LETIPharma: AIT beyond pollens and mites. A future of opportunities.
Monday, 8 June 2020 - 18.00-19.15 CET

Chair: Ralph Mösges, Germany

Rare Allergens: Diagnostic and Treatment
Ludger Klimek, Germany

Clinical experience with depigmented polymerized cat immunotherapy
Maria Vazquez de la Torre, Spain

Immunotherapeutic alternatives for rare allergens
Jeronimo Carnés, Spain

Q&A
All faculty



EAACI Digital Congress

6-8 June 2020



Bridging Innovations into Allergy and Asthma Prevention

#EAACI2020



Exhibitor & Sponsor List



Click on the icons
to access content



Platinum Founder Sponsors 2020

Virtual Exhibition

Digital Symposium

Allergy Therapeutics



AstraZeneca PLC



DBV Technologies



Novartis Pharma AG



Sanofi Genzyme / Regeneron



Stallergenes Greer



Gold Founder Sponsors 2020

Virtual Exhibition

Digital Symposium

Allergopharma GmbH & Co. KG



Silver Founder Sponsors 2020

Virtual Exhibition

Digital Symposium

LETIPharma



Exhibitors & Sponsors

Virtual Exhibition

Digital Symposium

DST



FAES FARMA



GSK



MacroArray Diagnostics



MSD



Nestlé Health Science



Pharming Group N.V.



Revenio Research / Ventica



Societies

Virtual Exhibition

Digital Symposium

American Academy of Allergy, Asthma and Immunology



European Respiratory Society (ERS)



AstraZeneca

Helping your patients with severe asthma

Visit the AstraZeneca
digital exhibition booth
to find out more





Allergopharma GmbH & Co. KG

Hermann-Körner-Straße 52
21465 Reinbek
Germany
+49 40 727650
www.allergopharma.com

Allergopharma is a German company that has been working successfully in allergy research, diagnostics and treatment for decades. We work alongside scientists and doctors to develop premium products for the allergy market which cover the entire treatment spectrum - from diagnostic tools to allergoids for allergen immunotherapy.

With all our passion and expertise, we strive to find the best possible treatment for allergies to help people enjoy a fulfilled life. From 2013 to 2020 Allergopharma was fully integrated into Merck as the Allergy Business Unit. Since April 2020 Allergopharma is a company of the Dermapharm Holding.

Allergy Therapeutics

Dominion Way
BN14 8SA, Worthing
United Kingdom
+44 1903 844 700
www.allergytherapeutics.com

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.

We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms.

Our adjuvant technologies not only advance the results of allergy immunotherapy but also drive beneficial immune responses in cancer and infectious disease.

We are a proud and passionate team of scientists and business specialists with a vision that delivers growth and transforms the way we think about immunology.

American Academy of Allergy, Asthma and Immunology

555 E. Wells St., Ste. 100
53202 Milwaukee
United States
+1 414 272 6071
www.aaaai.org

The American Academy of Allergy, Asthma & Immunology (AAAAI) is a professional organization with more than 7,000 members in the United States, Canada and 72 other countries. This membership includes allergist / immunologists, other medical specialists, allied health and related healthcare professionals - all with a special interest in the research and treatment of allergic and immunologic diseases.

AstraZeneca PLC

1 Francis Crick Ave
CB2 0RE, Cambridge
United Kingdom
+44 20 3749 5000
www.astrazeneca.com

Respiratory & Immunology is one of AstraZeneca's three therapy areas and is a key growth driver for the Company.

AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019.

Building on a 50-year heritage, the Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death. The Company's early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell repair processes in disease and neuronal dysfunction.

More Freedom in Life

Allergopharma. Allergies in Best Hands.



Exhibitor & Sponsor Editorials



DBV TECHNOLOGIES

Avenue Pierre Brossolette 177-181
92120, Montrouge
France
+33 1 55 42 78 78
www.dbv-technologies.com

DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy. We are committed to developing safe and effective therapies for food allergic patients. DBV is currently developing epicutaneous immunotherapy, or EPIT, which delivers biologically active compounds to the immune system through intact skin.

DST

Güterbahnhofstr. 16
19059, Schwerin
Germany
+49 385303480
www.dst-diagnostic.com

DST GmbH develops, manufactures and markets in-vitro diagnostics. The product portfolio includes different test systems for laboratory use as well as for point-of-care. Over 600 high quality allergens, produced and characterized in-house, form the basis for professional allergy diagnostics. Semi- and fully automatic test systems enable laboratories to detect human antibodies in serum or plasma samples by use of allergen-coated microtiter plates or strips. Point-of-care tests allow medical professionals to test their patients immediately and reliably with just a few drops of capillary blood.



AIT BEYOND POLLENS AND MITES. A FUTURE OF OPPORTUNITIES.

Chairman: Prof. Dr. Ralph Mösges, Germany

Rare allergens: diagnostic and treatment

Prof. Dr. Ludger Klimek, Germany

Clinical experience with depigmented polymerized cat immunotherapy

Dra. María Vázquez de la Torre, Spain

Immunotherapeutic alternatives for rare allergens

Dr. Jerónimo Carnés, Spain

June 8th at 18:00 CET



Nestlé Health Science Symposium at the EAACI Digital Congress 2020

New Advances in the Prevention and Management of Food Allergy

Sunday 7th June 2020 | 10:30 am – 11:45 am (CET)

Chairperson: Prof. Yvan Vandenplas | Belgium

How to Implement Nutritional Strategies for Food Allergy Prevention?

Dr. Carina Venter

Section of Allergy and Immunology
Children's Hospital Colorado
University of Colorado
Denver, CO, USA



Human Milk Oligosaccharides (HMO) for the Immune System Development

Dr. Norbert Sprenger

Nestlé Research
Vers-chez-les-Blanc, Lausanne
Switzerland



New Data on the Benefits of HMO in the Management of Cow's Milk Protein Allergy

Prof. Anna Nowak-Węgrzyn

Allergy and Immunology
Department of Pediatrics
Hassenfeld Children's Hospital
NYU Langone Health
New York, NY, USA



Exhibitor & Sponsor Editorials



European Respiratory Society (ERS)

Avenue Ste Luce 4
1003, Lausanne, Switzerland
+41 21 213 01 01
www.ersnet.org

The European Respiratory Society (ERS) is an international organisation that brings together physicians, health-care professionals, scientists and other experts working in respiratory medicine. It is one of the leading medical organisations in the respiratory field, with a growing membership representing over 170 countries worldwide. Its mission is to promote lung health in order to alleviate suffering from disease and drive standards for respiratory medicine globally.

FAES FARMA

Avenida Autonomia 10
48940, Leioa, Spain
+34 944818300
www.faesfarma.com

FAES FARMA is a leading Spanish pharmaceutical company with international projection, with more than a 1.100 employees, between its headquarters in Madrid, R&D&I centre in Bilbao and its subsidiary companies abroad. Bilastine, is the latest novelty. A new 2nd generation, non-sedating antihistamine, for children and adults, already present in more than 100 countries. Bilastine is an antihistamine that is used to relieve the symptoms of allergic rhinoconjunctivitis and to treat itchy skin rashes (wheals or urticaria). FAES FARMA works to offer highly effective solutions for the patients.

GSK

Great West Road 980
TW8 9GS, Brentford, Middlesex, United Kingdom
+44 2080475000
www.gsk.com

For over 50 years, GSK has led the way in the management and treatment of respiratory disease with the aim of helping people do more, feel better and live longer. At EAACI Digital Congress 2020, we will share the latest clinical evidence to advance the treatment of severe eosinophilic asthma (SEA), as we believe that every person with an eosinophilic driven disease should be able to live a fulfilling life. We invite you to join us at our satellite symposium on Sunday June 7th at 16:30 – 17:45 at CSS 11 and to learn more by visiting our virtual exhibition stand. (March 2020; PM-GBL-MPL-WCNT-200002)

LETIPharma

Gran Via de Les Corts Catalanes 184 – 7º planta
08038, Barcelona, Spain
+34 933940536
www.leti.com

LETIPharma is an independent and family-owned biopharmaceutical research company. In its different areas of expertise, it seeks to contribute products to society that add value to health care. Its headquarters are in Barcelona and its industrial plant and allergy research laboratory are in Tres Cantos (Madrid). It has subsidiaries in Germany (Ismaning and Witten) and Portugal (Oporto). LETIPharma operates with exclusive distributors in several countries in Europe, Latin America and Africa.

MacroArray Diagnostics

Lemböckgasse 59/Top 4
1230, Vienna, Austria
+43 8652573
www.macroarraydx.com

MacroArray Diagnostics is a Vienna-based MedTech company. We develop, produce, and distribute tests, instruments and software for allergy diagnostics and research applications. Our products allow flexible, reliable, and affordable sensitization profiling of each patient. Our multidisciplinary team ensures that customers receive the most advanced tools to fulfill their diagnostic needs.

More information
at our booth
in the digital
exhibition hall.





MSD

2000 Galloping Hill Road, K6-1-165
Kenilworth, NJ 07033
United States
+1 908 740 6223
www.msd.com

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world. For more information, visit our website and connect with us on Twitter, LinkedIn and YouTube.

Nestlé Health Science

Avenue Nestlé 55
1800, Vevey
Switzerland
+41 219244100
www.nestlehealthscience.com

Founded in 2011, Nestlé Health Science (NHSc) is a globally recognised leader in the field of nutritional science. We offer an extensive portfolio of science-based consumer health, medical nutrition and supplement brands. We currently produce over a billion nutritional health solutions for consumers, patients and their healthcare providers. NHSc is redefining the way we approach the management of health in several key areas, including the diagnosis, management and prevention of food allergy.

Novartis Pharma AG

4002, Basel
Switzerland
www.novartis.com

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world.

Pharming Group N.V.

Darwinweg 24
2333CR, Leiden
The Netherlands
+31 71 5247 400
www.pharming.com

Pharming is a specialty pharmaceutical company based in the Netherlands, developing innovative products for the treatment of rare diseases and unmet medical needs. We use transgenic technology to develop pioneering treatments, focusing on the development and production of human therapeutic proteins to provide life-changing solutions to patients. Founded in 1988, Pharming has experienced rapid growth recently, but our greatest asset remains our people. With a global workforce of more than 200 highly skilled people, we are committed to transforming the future for our patients.



Revenio Research / Ventica

Äyritie 22
01510, Vantaa
Finland
+35 820 730 5511
www.ventica.net

Revenio Research is part of Revenio Group Corporation, a Finnish health tech group listed on Nasdaq Helsinki. Our lung function test provides valuable information to support clinical decision-making in young children (5 years and younger) with recurrent wheeze and/or asthma. The test provides an easy-to-interpret, objective result after a nocturnal measurement at home. Today Revenio Group is well-known for tonometers used in ophthalmology. Our vision is to become the provider of choice for unique healthcare solutions.

Sanofi Genzyme / Regeneron

Binney Street 50
MA 02142, Cambridge
United States
+1 617 252 7500
www.sanofigenzyme.com

Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients' needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.

STALLERGENES GREER

Rue Alexis de Tocqueville 6
92183, Antony Cedex
France
+33 1 55 59 2000
www.stallergenesgreer.com

Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).



European Academy of Allergy
and Clinical Immunology
19-23 June 2021
MADRID



EAACI Congress 2021



[EAACI.org](https://eaaci.org)

[#eaaci2021](https://twitter.com/eaaci2021)